CJC-1295 ipamorelin on Reddit: the seven questions that keep coming back

1. "Does CJC-1295 and ipamorelin really work?"

Split the question in two. Does each peptide release growth hormone in people? Yes, and the numbers are clean. CJC-1295 with its albumin linker, in two randomized placebo-controlled trials in healthy adults, raised mean GH 2 to 10-fold for 6 days or more and IGF-1 1.5 to 3-fold for 9 to 11 days after one subcutaneous dose [Teichman et al., 2006]; a week after one 60 or 90 µg/kg dose, trough GH was 7.5-fold higher, mean GH 46 % higher and IGF-1 45 % higher [Ionescu et al., 2006].

Ipamorelin, infused intravenously into healthy men, produced one GH episode at every dose, peaking at 0.67 hours [Gobburu et al., 1999]. Does the pair, as sold, do anything measurable in people? Nobody knows, because no published study has given the two together; the synergy idea comes from GHRH(1-44) plus GHRP-6 in 18 men in 1990 [Bowers et al., 1990]. And does any of it translate into muscle, fat or sleep? For these molecules, no study has looked. The thread answer "it works" is usually the first of those three questions; the thread question is usually the third.

2. "DAC or no DAC for the blend?"

No DAC, and the reason is arithmetic. The DAC form binds albumin and lasts 5.8 to 8.1 days [Teichman et al., 2006]; ipamorelin lasts about 2 hours [Gobburu et al., 1999]. A pair is supposed to act on the same GH pulse, and a molecule that lingers for a week is acting on all of them. Threads sometimes argue that the DAC form gives "more total GH", which is true as far as the trough data go, but it is a different pharmacology, not a stronger version of the same one. The chemistry and the trade-offs are in CJC-1295 DAC versus no DAC.

3. "How long does it take to see results?"

There is no published answer, because no trial measured a visible outcome for either peptide, let alone the pair. The time-course data that exist are hormonal. After one CJC-1295 dose, GH was up within the first sampling day and IGF-1 stayed above baseline for 9 to 11 days; after repeated weekly or biweekly doses, for up to 28 days [Teichman et al., 2006].

The parent GHRH(1-29) sequence, the closest published relative of the linker-free peptide in the blend, took 14 days of twice-daily 1 mg injections to restore GH and IGF-1 in men aged 68 to the values of men in their twenties [Corpas et al., 1992]. Any thread that gives a number of weeks for "results" is describing its author's experience, which is not nothing, but it is not a measurement either.

4. "Does it affect testosterone? Does it raise cortisol?"

Testosterone: nothing published, for either peptide, in humans. The nearest data are from swine, where ipamorelin did not change FSH or LH, the pituitary hormones that govern testosterone [Raun et al., 1998]. Cortisol: this is the question ipamorelin was designed to answer. Earlier GHRPs raised ACTH and cortisol along with GH; GHRP-6 roughly doubled cortisol and prolactin in men at 1 µg/kg [Bowers et al., 1990]. Ipamorelin, in swine, left ACTH and cortisol at GHRH-reference levels even at more than 200 times its ED50 for GH [Raun et al., 1998]. That is a strong animal result from the manufacturer; it has never been repeated in a human study, and threads that state "ipamorelin doesn't raise cortisol" as a human fact are extrapolating.

5. "Do you build a tolerance to it?"

One published signal, in rats. After 15 days of ipamorelin three times daily, the GH response to a test dose of ipamorelin was marginally reduced (P < 0.03) while the response to GHRH was unchanged and the pituitary's GH content was normal [Johansen et al., 1999]. So the ghrelin receptor can become slightly less responsive with repeated stimulation, the GHRH receptor in that experiment did not, and the gland was not depleted.

For CJC-1295 the opposite question was studied: does a week of continuous stimulation exhaust the response? One week after a single dose, pulses were intact and the trough was up 7.5-fold [Ionescu et al., 2006], and in GHRH-knockout mice daily dosing for 5 weeks increased pituitary GH mRNA rather than depleting it [Alba et al., 2006]. Human data on tolerance over weeks or months do not exist for either peptide.

6. "What are the downsides of CJC-1295?"

From the trials, at the doses studied: no serious adverse reactions, and the authors' judgement that 30 and 60 µg/kg were "safe and relatively well tolerated" [Teichman et al., 2006]. The class effects of GHRH analogues are flushing, in 16 of 18 men after GHRH(1-44) in the 1990 study [Bowers et al., 1990], and injection-site reactions.

What is not known is the consequence of a raised GH trough sustained for months, because the programme that would have found out was terminated in 2006. For ipamorelin the largest safety dataset is 114 surgical patients in whom adverse events were no more frequent than with placebo, 87.5 % against 94.8 % [Beck et al., 2014]. Both pages of this site that deal with adverse effects, CJC-1295 side effects and ipamorelin side effects, list what was measured and what was not.

7. "Is it legal, and how do I know the vial is real?"

Neither peptide is an approved medicine anywhere. In the United States they are sold as research chemicals, labelled not for human consumption; the FDA placed ipamorelin acetate in category 2 of its compounding bulk-substances list on September 29, 2023, citing possible immunogenicity [U.S., 2023], and both molecules are named in class S2 of the WADA Prohibited List [World, 2026].

As for the vial: a blend certificate has to show two HPLC peaks and two masses, near 3,368 for the linker-free CJC-1295 and 711.9 for ipamorelin, from a named laboratory, with the lot number that is on the vial. Threads that recommend a supplier by name are recommending their own experience; a certificate is a document anyone can read. The nine things a listing must say are in CJC-1295 ipamorelin for sale.

Seven questions, seven answers, and in four of them the honest answer includes "not measured in humans". That is the difference between a thread and the literature, and it is why this site exists.

Questions or corrections: editor@cjc-1295-ipamorelin.com. See the editorial policy.